共 84 条
[1]
Goutsouliak K(2020)Towards personalized treatment for early stage HER2-positive breast cancer Nat Rev Clin Oncol 17 233-250
[2]
Veeraraghavan J(2020)HER2-positive advanced breast cancer treatment in 2020 Cancer Treat Rev 88 102033-1205
[3]
Sethunath V(1987)Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 389 1195-S353
[4]
Cesca MG(2017)11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Lancet 31 S352-1137
[5]
Vian L(2020)279MO Divergent evolution of overall survival across metastatic breast cancer (MBC) subtypes in the nationwide ESME real life cohort 2008–2016 Ann Oncol 28 1131-246
[6]
Cristóvão-Ferreira S(2010)Open-label, phase ii, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2–negative metastat J Clin Oncol 6 240-453
[7]
Slamon DJ(2005)Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab Clin Breast Cancer 38 444-1896
[8]
Clark GM(2020)NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and With IHC 1+ or 2 J Clin Oncol Off J Am Soc Clin Oncol 38 1887-1135
[9]
Wong SG(2020)Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study J Clin Oncol Off J Am Soc Clin Oncol 20 1124-1962
[10]
Cameron D(2019)Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study Lancet Oncol 38 1951-2122